No they technically don’t, but the meeting also discussed the ‘Adult’ aGVHD trial progression and not just the Paeds aGVHD data and BLA.
I am keen to receive an update on the FDA’s thoughts on MSB’s methodology and progression of the trial. It also may give us more confirmation about MSB’s assay approach and FDA’s ongoing thoughts here.
If you know what I mean.
Mesoblast stock(rock)-take March 2024, page-138
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.080(6.50%) |
Mkt cap ! $1.321B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.20 | $1.15 | $6.692M | 5.738M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 224613 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 33956 | 10 |
View Market Depth
| Last trade - 11.52am 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
-0.080 ( 6.44 %) |
||||
| Open | High | Low | Volume | ||
| $1.20 | $1.20 | $1.15 | 594909 | ||
| Last updated 12.12pm 30/05/2024 ? | |||||
| MSB (ASX) Chart |